You're certainly a glass half full guy.
IMU has been targeting rare indications because their "me-too" drugs either:
- can't compete against the big boys already approved in the larger markets (HER-VAXX, PD1-VAXX)
- aren't as advanced and playing catch up against other clinical opportunities (Azercel).
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
26.5¢ |
Change
-0.015(5.36%) |
Mkt cap ! $76.45M | |||
| Open | High | Low | Value | Volume |
| 28.0¢ | 28.0¢ | 26.5¢ | $328.6K | 1.213M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 33 | 595083 | 26.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 194687 | 15 |
View Market Depth
| Last trade - 13.07pm 31/07/2025 (20 minute delay) ? |
| IMU (ASX) Chart |